The S&P 500 eked out a 1.5-point gain Monday to strike yet another record high as a fresh round of mergers and acquisitions fueled optimism in the markets.
- S&P 500 Hits New Record High on Fresh Round of Deals
- These Biotech Stocks Are Tied to the World’s Most Expensive New Drugs
- This New Alzheimer's Drug Could Be the Fastest Route to a Treatment Breakthrough
- Merck (MRK) Shares Rise, Pfizer (PFE) Stock Slumps on Mixed Earnings
- Time to Profit (Again) from the "ASCO Effect"
- AAPL, GWPH, FDO Among Hot Stocks on the Move Today
- Top News Affecting the Dow Jones Today
- Seven Biotech Stocks to Watch Based on "Game-Changing" Cancer Treatment Updates
One of the reasons biotech stocks can be your portfolio’s biggest winners is because of the massive profits companies see after releasing a blockbuster drug – especially with the exorbitantly high prices of this year’s new treatments.
Just last week, two major pharmaceutical companies announced that they are working together on a new Alzheimer's drug - and that's great news. But it may be a decade away from becoming reality.
But another biotech company is zooming ahead in the race for the cure - and its drug is in late-stage phase 3 trials.
Two American pharmaceutical giants reported earnings this morning, both showing flagging sales - but one ended the day with a gain.
The American Society of Clinical Oncology meets every spring. It's attended by some 30,000 people and hosts 4,000 presentations.
Investors like us love ASCO because of the so-called "ASCO Effect" - a hefty surge in cancer-focused biotech stocks that always accompanies the start of this meeting.
And we usually recommend an oncology stock or two ourselves.
This year's ASCO turned us on to an important new trend - one that's shaping up as the next big profit opportunity in biotech. Full Story
Today's hot stocks: It's Monday on Wall Street, and that typically means a flurry of mergers and acquisitions.
Indeed, several deals were announced today and are featured on our hot stocks to watch list - one surging some 236%. Meanwhile, a penny stock deemed the next likely takeover candidate amid the rash of healthcare M&A soared 42%.
Stock market today, June 9, 2014: The Dow Jones is set to kick off the week after reaching a record high on Friday along with the S&P 500. A positive jobs report and increased support from the European Central Bank factored into the climb.
A number of promising cancer treatments were presented this week by key global pharmaceutical players at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) - which is why this is a key time of year to watch a specific group of biotech stocks.
The event, which this year took place May 30 - June 3, is attended by thousands of renowned oncologists, researchers, analysts, and investors. It is unquestionably the most highly anticipated and most news-generating cancer research meeting of the year.
ASCO can deliver a blockbuster, breakout drug that will not only lead to better cancer treatments, but one that will also bring in billions of dollars in revenue. Moreover, there's also the potential of a drug's developer becoming a profitable takeover target.